留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

肝细胞癌术后复发再次手术1例及文献综述

郭玲玲 丁永梅 张迁

郭玲玲, 丁永梅, 张迁. 肝细胞癌术后复发再次手术1例及文献综述[J]. 药学实践与服务, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
引用本文: 郭玲玲, 丁永梅, 张迁. 肝细胞癌术后复发再次手术1例及文献综述[J]. 药学实践与服务, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
Citation: GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019

肝细胞癌术后复发再次手术1例及文献综述

doi: 10.3969/j.issn.1006-0111.2017.03.019

Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review

  • 摘要: 肝细胞癌是中国及全球范围内发病率很高的恶性肿瘤。手术切除一直是治疗肝细胞癌的标准治疗,随着手术技术与支持手段的发展,围手术期风险显著降低,但是术后生存率却不高,高复发率是导致死亡的主要原因。笔者报道了一例肝细胞癌术后复发再行手术等多种治疗的病例,并对肝细胞癌术后复发的危险因素和治疗的新进展进行综述。
  • [1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
    [2] Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance[J]. Gastroenterology, 2004, 126(4): 1005-1014.
    [3] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.
    [4] Carr BI. Hepatocellular carcinoma: current management and future trends[J]. Gastroenterology, 2004, 127(5 Suppl 1): S218-224.
    [5] Gluer AM, Cocco N, Laurence JM, et al. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma[J]. HPB (Oxford), 2012, 14(5): 285-290.
    [6] Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation[J]. Hepatology, 1999, 30(6): 1434-1440.
    [7] Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(19): 1995-2004.
    [8] Sun HC, Tang ZY, Ma ZC, et al. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background[J]. J Cancer Res Clin Oncol, 2005, 131(5): 284-288.
    [9] Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma[J]. Ann Surg, 2003, 238(5): 703-710.
    [10] Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors[J]. Ann Surg, 1999, 229(2): 216-222.
    [11] Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma[J]. Ann Surg Oncol, 2007, 14(8): 2337-2347.
    [12] Shah SA, Greig PD, Gallinger S, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes[J]. J Am Coll Surg, 2006, 202(2): 275-283.
    [13] Bellavance EC, Lumpkins KM, Mentha G, et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?[J]. J Gastrointest Surg, 2008, 12(10): 1699-1708.
    [14] Li Q, Li H, Qin Y, et al. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience[J]. J Gastroenterol Hepatol, 2007, 22(11): 1936-1941.
    [15] Chong CC, Lee KF, Ip PC, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier?[J]. Surgeon, 2012, 10(5): 260-266.
    [16] Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group[J]. N Engl J Med, 1996, 334(24): 1561-1567.
    [17] Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet, 2000, 356(9232): 802-807.
    [18] Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma[J]. Ann Surg, 2003, 238(6): 885-893.
    [19] Yang W, Chen MH, Yin SS, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence[J]. AJR Am J Roentgenol, 2006, 186(5 Suppl): S275-283.
    [20] Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
    [21] Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5): 1164-1171.
    [22] Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015, 148(7): 1383-1391.
    [23] Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology, 2014, 60(5): 1776-1782.
    [24] Jiang G, Xu X, Ren S, et al. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma[J]. Tumour Biol, 2014, 35(4): 3405-3408.
    [25] Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J]. J Hepatol, 2014, 61(2): 309-317.
    [26] Hatzaras I, Bischof DA, Fahy B, et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21(3): 758-766.
  • [1] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [2] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
    [3] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [4] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [5] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [6] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 1-6. doi: 10.12206/j.issn.2097-2024.202308062
    [7] 王鹏, 陈顺, 赵逸, 高守红, 王志鹏.  卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(8): 1-5. doi: 10.12206/j.issn.2097-2024.202308045
    [8] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [9] 顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩.  侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
    [10] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [11] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
  • 加载中
计量
  • 文章访问数:  2633
  • HTML全文浏览量:  352
  • PDF下载量:  881
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-10-20
  • 修回日期:  2017-03-07

肝细胞癌术后复发再次手术1例及文献综述

doi: 10.3969/j.issn.1006-0111.2017.03.019

摘要: 肝细胞癌是中国及全球范围内发病率很高的恶性肿瘤。手术切除一直是治疗肝细胞癌的标准治疗,随着手术技术与支持手段的发展,围手术期风险显著降低,但是术后生存率却不高,高复发率是导致死亡的主要原因。笔者报道了一例肝细胞癌术后复发再行手术等多种治疗的病例,并对肝细胞癌术后复发的危险因素和治疗的新进展进行综述。

English Abstract

郭玲玲, 丁永梅, 张迁. 肝细胞癌术后复发再次手术1例及文献综述[J]. 药学实践与服务, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
引用本文: 郭玲玲, 丁永梅, 张迁. 肝细胞癌术后复发再次手术1例及文献综述[J]. 药学实践与服务, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
Citation: GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
参考文献 (26)

目录

    /

    返回文章
    返回